Diabetes and CVD

Diabetes and CVD module 1: epidemiology

Released 10 February 2021 Programme: Diabetes and CVD 1 CPD/CME credit

Prevalence and risk factors for developing type 2 diabetes
Diagnostic criteria for type 2 diabetes including the use of HbA1c
Pathogenesis of type 2 diabetes
Role of type 2 diabetes along with co-morbidities in defining an individual’s cardiovascular risk
The evidence for treating to glycaemic targets
Problem of heart failure in type 2 diabetes
Rationale for cardiovascular outcome trials (CVOTs) and approaches to modern management in type 2 diabetes

Released 10 February 2021 Programme: Diabetes and CVD 2 CPD/CME credits

Outline the mechanism of action, dose and side effects for each of the main classes of anti-diabetic drugs
Outline the rationale for use or contra-indications of these drugs in patients with cardiovascular disease (more details will be given in modules 3 and 4).
Discuss the use of each class of drugs in patients with chronic kidney disease

Released 10 February 2021 Programme: Diabetes and CVD 1 CPD/CME credit

Review the results of cardiovascular outcome trials (CVOTs) with DPP-4 inhibitors
Review the results of key CVOTs with GLP-1 receptor agonists including LEADER, SUSTAIN-6, and REWIND
Compare results with SGLT2 inhibitor CVOTs
Define patients who would benefit from treatment with GLP-1 receptor agonists

Released 10 February 2021 Programme: Diabetes and CVD 1 CPD/CME credit

Review the results of cardiovascular outcome trials (CVOTs) with SGLT2 inhibitors in people with diabetes, including EMPA-REG OUTCOME, CANVAS and DECLARE-TIMI 58
Asses the results of trials of SGLT2 inhibitors in patients with renal disease, including CREDENCE and DAPA-CKD
Asses the results of trials of SGLT2 inhibitors in patients with heart failure, including DAPA-HF and EMPEROR-Reduced
Define patients who would benefit from treatment with SGLT2 inhibitors